Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.31 |
| ▸ | IDH1 | O75874 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KLK7 | P49862 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17186284 | 0.99 | SIGMAR1 (0.35) | SIGMAR1KDM5BPDE4APDE4BPDE4C | |
| SCHEMBL17186408 | 0.81 | MGMT (0.40) | SIGMAR1PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL18605989 | 0.81 | MGMT (0.40) | SIGMAR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6811648 | 0.79 | KDM5B (0.33) | KDM5BALOX5 | |
| SCHEMBL5021599 | 0.78 | ADORA2B (0.43) | PDE4APDE4BPDE4CPDE4DPIK3CD | |
| SCHEMBL9806961 | 0.77 | ADORA2B (0.36) | PDE4APDE4BPDE4CPDE4DPIK3CD | |
| SCHEMBL6751928 | 0.76 | ADORA2B (0.35) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL441795 | 0.76 | ADORA2B (0.35) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL17186305 | 0.73 | PNP (0.39) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17186215 | 0.72 | CHRM2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | claimed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | claimed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | claimed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | SIGMAR1 4102/4885KDM5B 1084/4885PDE4A 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.